The FDA should work with other regulatory bodies, especially the European Medicines Agency (EMA), to create a single marketing application that would be accepted by multiple regulators, drug industry insiders urge.
The Biotechnology Industry Organization (BIO) wants the agency to harmonize both the content and structure of drug applications so sponsors can submit the same dossier to several agencies. This would allow drugmakers and regulatory agencies to save resources. The trade group commented in response to the FDA’s request for suggestions to modernize the regulation of clinical trials and approaches to good clinical practice (GCP).
A harmonized application could bring medical products to market sooner, Pfizer U.S. Regulatory Policy Director Carol Haley noted in the company’s comments.
The industry giant suggested the FDA and EMA pilot a project to develop a marketing application acceptable to both agencies and then accept two or three drug applications for dual review each year. The drug regulators would still retain their individual authority to approve or deny an application. Such a pilot would require that the two agencies develop consistent GCP standards, Pfizer said.
With the push for improved compliance and enforcement — and a legion of newly hired and trained investigators — the FDA is coming down hard on sponsors and sites to comply with GCP.
But with limited budgets, training directors are having a hard time finding cost-effective training tools to educate their staff. There is an easier way. Now you can train staff yourself — for significantly less money — in your own office, on your own schedule.
Get FDAnews’ Clinical Trial Training Series we’ve pulled the “best of” our webinar and virtual conference recordings and packaged them together. With nearly 15 hours of content, the Clinical Trials Training Series is a cost-effective way to give your staff the kind of high-level education they want and need … with the flexibility that makes in-house training most beneficial. Don’t wait, order this must-have tool today.